Clinical trial
A Phase 1, Randomized, Blinded, Placebo-Controlled, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APR002 Administered by Inhalation in Healthy Volunteers
NCT05268198 is registered in ClinicalTrials.gov with Global Health Drug Discovery Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Blinded, Placebo-Controlled, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APR002 Administered by Inhalation in Healthy Volunteers
- Lead sponsor
- Global Health Drug Discovery Institute
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 20, 2023
- Completion date
- July 27, 2023
- Enrollment
- 42 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.